Human‑Milk‑Inspired Antimicrobial Peptides for Bacterial Vaginosis: Preclinical Reporting

Preclinical experiments of human‑milk‑inspired antimicrobial peptides evaluated computationally designed, cationic candidates intended for topical bacterial vaginosis (BV) applications, highlighting UCD‑MAT‑001, UCD‑MAT‑002, MAT‑006, and MAT‑014 as lead sequences. The authors report bactericidal effects against BV-associated bacteria alongside differential activity across vaginal lactobacilli, and they describe mechanistic fluorescence readouts, resistance-selection work, stability experiments, and testing in human-relevant epithelial and organotypic models. Across the article, these datasets are presented as a preclinical package to characterize spectrum, selectivity, and early tolerability signals.

In standardized in vitro microbicidal testing, the investigators report that the lead peptides were bactericidal against Gardnerella vaginalis and additional BV-associated organisms tested, with minimal bactericidal concentrations described as falling in a low-microgram-per-milliliter range (≈8–32 μg/mL, varying by peptide and pathogen) under their assay conditions using diluted media and related buffers. For selectivity, the authors describe that UCD‑MAT‑001, UCD‑MAT‑002, and MAT‑006 did not reduce viability of Lactobacillus crispatus, L. gasseri, and L. jensenii in their in vitro experiments, whereas MAT‑014 showed bactericidal activity toward those lactobacilli in the study’s testing. The paper also details mixed-culture experiments using a co-culture setup and selective plating media to track pathogen versus lactobacilli growth over time following peptide exposure. In aggregate, the authors frame these assays as showing in vitro bactericidal activity against BV-associated pathogens, with selective activity reported for UCD‑MAT‑001, UCD‑MAT‑002, and MAT‑006 versus the tested healthy vaginal lactobacilli under the study conditions (in contrast, MAT‑014 appeared bactericidal toward those lactobacilli).

To connect activity to a proposed mode of action, the authors describe fluorescence-based membrane assays and interpret them as consistent with membrane-centered effects. They report N-phenyl-1-naphthylamine (NPN) uptake signals as consistent with membrane permeabilization and DiBac4(3) signals as consistent with membrane depolarization in the tested bacteria. In a separate biofilm experiment, MAT‑006 was reported to reduce G. vaginalis biofilm after a 1-hour exposure at concentrations near its bactericidal levels (≈20 μg/mL in the figure presented), using crystal-violet staining and absorbance-based quantification. The paper presents these fluorescence and biofilm findings together as supporting a membrane-active antimicrobial profile in the assays performed.

For resistance selection, the sutdy reports a serial-passaging experiment in which the authors did not detect resistance emergence to MAT‑006 under their study conditions, while a metronidazole control condition showed measurable resistance in the same assay framework. The article also describes peptide stability testing across storage and temperature-shift conditions, reporting retained bactericidal properties after the tested exposures. On host-relevant tolerability readouts, the authors report no loss of viability in VK2/E6E7 vaginal epithelial and HeLa cervical epithelial monolayers at peptide concentrations up to 10 mg/mL in their calcein-based assay, and an ET50 of >24 hours for all four peptides in a MATTEK EpiVag organoid model using an MTT time-course approach at tested concentrations. In an in vitro infection model using G. vaginalis with VK2/E6E7 monolayers, the authors report reduced induction of IL‑6, IL‑8, TNFα, and IL‑1β when peptides were present. The discussion describes formulation into vaginal inserts and additional safety/efficacy evaluation as next steps, and it closes with a forward-looking development rationale.

Key Takeaways:

• The authors report that select lead peptides were bactericidal to BV-associated organisms while sparing several Lactobacillus species in the described in vitro assays and co-culture plating experiments.
• Mechanistic fluorescence assays and serial-passaging experiments are presented as consistent with membrane-active effects, and the authors report that resistance emergence to MAT‑006 was low and not detectable in their assays under the study conditions.
• Epithelial cell lines and an organotypic vaginal tissue model showed reported tolerability, infection-model experiments showed reduced inflammatory marker induction, and the discussion describes formulation and further testing as next steps.